Our Leading Drug Candidates: LJPC-501, GCS-100, LJPC1010, and LJPC-401
Our drug development efforts are focused on four product candidates, LJPC-501, GCS-100, LJPC-1010, and LJPC-401. Our lead product, LJPC-501, is a peptide agonist of the renin-angiotensin system that acts to help the kidneys balance body fluids and electrolytes. Our second product candidate, GCS-100, focuses on modulation of galectin-3, a member of the galectin family of proteins. Our third product candidate, LJPC-1010 is a more potent and purified derivative of GCS-100 that can be delivered orally. Our fourth product candidate, LJPC-401, is a formulation of Hepcidin, a endogenous peptide hormone that regulates dietary iron absorption and tissue distribution.